Ovarian Cancer, Peritoneal Carcinomatosis
Conditions
Brief summary
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first). In the expansion cohort the subject will receive the recommended dose. The expansion cohort will be conducted at 4 sites. Each subject will be followed until disease progression (in the abdominal cavity), or for 24 months after the administration of Radspherin® (whichever comes first).
Detailed description
The maximum number of subjects enrolled in this study is 49. The following number of subjects will be recruited in the different cohorts: * Dose escalation cohorts: 3 - 24 Subjects * Expansion cohort: Up to 25 Subjects
Interventions
DRUGRadspherin
Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
Sponsors
Oncoinvent Solutions AS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
3+3 dose escalation study followed by an expansion cohort.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able and willing to provide written informed consent and to comply with the clinical study protocol 2. Age ≥ 18 years 3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal carcinoma 4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking surgery to R0. 5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy at time of first administration of Radspherin® 6. ECOG Performance Status Score of 0 - 1 7. Adequate renal function * Creatinine ≤ 1.8 mg/dl (159 μmol/l) and * calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or * measured creatinine clearance ≥ 45 ml/min 8. Adequate hepatic function * Serum bilirubin \<1.5 x upper limit of normal (ULN) * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN 9. Adequate bone marrow function: * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/l * Platelets ≥ 100 x 10\^9/l * Haemoglobin ≥ 9 g/dL 10. Adequate coagulation tests: INR ≤ 1.5 x ULN 11. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment 12. For females of childbearing potential who have a male partner: agreement to use two adequate methods of contraception (e.g. barrier, intrauterine device, hormonal implants, combined oral contraceptives or vasectomized partner), during the treatment period and for at least 3 months after the last dose of IMP.
Exclusion criteria
1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors, Sex-cord tumors) 2. Tumors of borderline malignancy 3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic lymph nodes are acceptable, except thoracic lymph nodes. 4. Pregnant or lactating (nursing) women 5. Active infections requiring antibiotics, and/or physician monitoring or recurrent fever \>38.0 ⁰C associated with a clinical diagnosis of active infection 6. Active liver disease with positive serology for active hepatitis B, hepatitis C or known HIV 7. Administration of an investigational medicinal product within 28 days, or at least 5 times the half-life, prior to enrolment 8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the last study treatment 9. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer) 10. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease 11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise the safety of the subjects or interfere with the evaluation of the safety of the IMP 12. In the Investigator's opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent 13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS 14. Known hypersensitivity to any of the excipients in the study drug 15. Persons who have been placed in an institution under an official or judicial order 16. Persons who are dependent on the sponsor financially must be excluded from participation 17. Persons with active SARS-CoV-2 infection must be excluded from participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0. | 24 months | To investigate safety and toxicity of Radspherin® |
| Maximum Tolerated Dose (MTD) | 21 days | To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS) |
Countries
Belgium, Norway, Spain
Outcome results
None listed